Side Effects of bicalutamide: A Synthesis of Findings from 27 Studies

  1. Home
  2. Side Effects of bicalutamide
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of bicalutamide: A Synthesis of Findings from 27 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of bicalutamide: A Synthesis of Findings from 27 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Bicalutamide is an antiandrogen medication commonly used for the treatment of prostate cancer. 10 While it is effective in treating advanced prostate cancer, it can cause side effects such as fatigue, gynecomastia, and decreased libido. 10 A rare but serious side effect is drug-induced liver injury. 10 The onset of liver injury may be delayed, occurring months after treatment initiation. 10

Bicalutamide has also been used to treat precocious puberty in boys. 21 In a case study, bicalutamide combined with anastrozole was found to effectively normalize growth velocity, reduce penile androgenization, and stabilize testicular volume in a boy with McCune-Albright Syndrome. 21 This combination was well-tolerated with no reported side effects. 21 However, in another case study involving a 5-year-old boy with familial male-limited precocious puberty, the combination of anastrozole and bicalutamide showed a clinical response with decreased advancement of skeletal maturation, secondary sexual characteristics, and aggressiveness, but further long-term data is needed. 24

Bicalutamide has also been implicated in masking the diagnosis and treatment of prostate cancer. 19 In a case report, a patient with recurrent ischemic priapism was treated with antiandrogens. 19 The antiandrogen therapy caused adverse side effects and likely masked elevated PSA levels, resulting in a delay in the diagnosis and treatment of prostate cancer. 19

Reasons for Side Effects

Bicalutamide is an androgen receptor antagonist. It works by blocking androgen receptors, preventing androgen from binding. 10 This blockage disrupts the natural hormonal balance in the body, leading to various side effects.

General Side Effects

Fatigue

Fatigue is a common side effect of bicalutamide. 10

Gynecomastia

Gynecomastia (breast enlargement) is another common side effect. 10 , 14

Decreased Libido

Decreased libido is a side effect that can impact sexual health and well-being. 10 , 12

Hallucinations

Hallucinations are a less common but serious side effect. 4

Liver Damage

Liver damage can occur, potentially with a delayed onset. 10

Countermeasures for Side Effects

Fatigue

If you experience persistent fatigue, consult your doctor. They can investigate the underlying cause and recommend appropriate management.

Gynecomastia

Consult your doctor if you experience breast enlargement. They can determine the cause and suggest treatment options.

Decreased Libido

Discuss your concerns about decreased libido with your doctor. They can assess the cause and explore possible solutions.

Hallucinations

Hallucinations should be reported to your doctor immediately. They can evaluate your condition and provide appropriate medical attention.

Liver Damage

If you experience any symptoms suggestive of liver damage, such as yellowing of the skin or eyes, abdominal pain, or dark urine, seek immediate medical attention.

Comparison between Studies

Commonalities between Studies

Multiple studies have documented fatigue, gynecomastia, and decreased libido as common side effects of bicalutamide. 10 , 14 , 12

Differences between Studies

The frequency and severity of side effects can vary between studies. 10 Some studies highlight the potential for liver damage, while others do not. 10 Further research is needed to comprehensively understand the variability of bicalutamide side effects.

Precautions for Real-life Applications

Bicalutamide is a powerful medication with potential side effects. It is crucial to take it as prescribed by your doctor and to be aware of potential symptoms. If you experience any concerning changes in your health while taking bicalutamide, promptly consult your doctor.

Limitations of Current Research

Research on bicalutamide side effects is ongoing. More studies are needed to fully understand the long-term effects of bicalutamide and the full spectrum of its potential side effects.

Future Research Directions

Further research is needed to address the following:

  • Comprehensive analysis of the frequency and severity of bicalutamide side effects.
  • Identification of specific risk factors for bicalutamide side effects.
  • Development of strategies to prevent or mitigate bicalutamide side effects.
  • Exploration of alternative treatment options to minimize side effect burden.

Conclusion

Bicalutamide is an important treatment for prostate cancer, but it is essential to be aware of its potential side effects. Careful monitoring, timely reporting of any health changes, and ongoing research are crucial for optimizing the use of bicalutamide and ensuring patient safety.

Literature analysis of 27 papers
Positive Content
22
Neutral Content
2
Negative Content
3
Article Type
1
0
1
3
26
4.

Bicalutamide-associated hallucinations in a metastatic prostate cancer patient: A case report.

Author: TurkkanGorkem, DoganCaner, TekBurak

LHRH agonist
Prostate cancer treatment
Bicalutamide
Hallucinations

This case report describes a patient with metastatic prostate cancer who developed hallucinations due to bicalutamide use. The hallucinations resolved after discontinuation of bicalutamide, and the patient experienced a good response with luteinizing hormone-releasing hormone agonist monotherapy.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Radiotherapy Plus GnRH Analogue <i>Versus</i> High Dose Bicalutamide: A Case Control Study.

Author: BuwengeMilly, DeodatoFrancesco, MacchiaGabriella, SiepeGiambattista, ZhaoXiao, ValicentiRichard K, CillaSavino, AlittoAnna Rita, NtretaMaria, BiselloSilvia, MantiniGiovanna, ValentiniVincenzo, MorgantiAlessio G, CammelliSilvia

Prostate cancer treatment

This study compared the results of prostate cancer (PC) patients treated with radiotherapy (RT) plus gonadotrophin-releasing hormone agonist (GnRHa) versus those treated with RT plus bicalutamide.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Light-activated ruthenium (II)-bicalutamide prodrugs for prostate cancer.

Author: ZhaoJian, LiuNannan, SunShuchen, GouShaohua, WangXinyi, WangZhimei, LiXiaoyan, ZhangWenjing

Enhanced drug efficacy
Reduced side effects
Reduced toxicity

This study describes the development of a photoactivatable drug delivery system for bicalutamide, an anticancer drug used for prostate cancer. The researchers synthesized three Ru(II) complexes that can bind to bicalutamide and release it upon irradiation with light. This light-activated release allows for targeted drug delivery and may potentially enhance therapeutic efficacy while reducing side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Idiopathic gonadotropin-independent precocious puberty - is regular surveillance required?

Author: AryaVed Bhushan, DaviesJustin H

Gonadotropin-independent precocious puberty treatment
Germ cell tumours
Precocious puberty

A 5.7-year-old boy with gonadotropin-independent precocious puberty (GIPP) had elevated serum β-HCG. After initial treatment failures, a combination of anastrozole and bicalutamide successfully normalized β-HCG and testosterone levels, highlighting the potential for these drugs in idiopathic GIPP.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

8.

Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity <i>In Vitro</i> and Tissue Selectivity <i>In Vivo</i>.

Author: DartD Alwyn, KandilSahar, Tommasini-GhelfiSerena, Serrano de AlmeidaGilberto, BevanCharlotte L, JiangWenguo, WestwellAndrew D

SK33 efficacy
SK51 efficacy

Novel chemically modified enobosarm analogues, SK33 and SK51, showed potent antiandrogenic activity and are ideal candidates for further development for prostate cancer therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

[An Undeniable Case of Optic Neuropathy Due to Cabazitaxel].

Author: NoguchiYusuke, KawashimaYugo, KawaraHiroko, KanekoMasatomo, NakauchiHiroo, TokuyamaYoko

Treat prostate cancer
Optic neuropathy

This case report describes a 78-year-old man who developed optic neuropathy during cabazitaxel treatment for prostate cancer. This is the first report of optic neuropathy associated with cabazitaxel. This case highlights the need for careful monitoring for eye disorders during taxane-type antineoplastic agent administration.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Japanese

10.

Atypical onset of bicalutamide-induced liver injury.

Author: YunGee Young, KimSeok Hyun, KimSeok Won, JooJong Seok, KimJu Seok, LeeEaum Seok, LeeByung Seok, KangSun Hyoung, MoonHee Seok, SungJae Kyu, LeeHeon Young, KimKyung Hee

Treatment of advanced prostate cancer
Decreased libido
Fatigue
Gynecomastia
Hepatotoxicity

A case of hepatotoxicity secondary to bicalutamide use is reported, highlighting the potential for delayed liver injury after 5 months of treatment. Careful monitoring of liver function is recommended throughout bicalutamide treatment for prostate cancer.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.

Author: WenSimeng, TianJing, NiuYuanjie, LiLei, YehShuyuan, ChangChawnshang

PCa metastasis suppression
Side effects of Casodex/Enzalutamide

This study investigates the role of prostate cancer stem/progenitor cells in androgen deprivation therapy (ADT) resistance. The study found that ADT with Casodex or Enzalutamide increased PCa S/P population, while ASC-J9(®) suppressed S/P cell invasion by altering EZH2/STAT3 and AKT/EZH2/STAT3 signals.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia?

Author: MotofeiIon G, RowlandDavid L, GeorgescuSimona R, TampaMircea, BaleanuBogdan C, PaunicaStana

Sexual side effects

Finasteride, a medication used to treat male pattern baldness, can cause sexual side effects. This study suggests that hand preference and sexual orientation may be associated with an increased risk of these side effects.

LetterA written message for communication and exchange of information between individuals.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005.

Author: ChangKun, QinXiao-Jian, ZhangHai-Liang, DaiBo, ZhuYao, ShiGuo-Hai, ShenYi-Jun, ZhuYi-Ying, YeDing-Wei

Longer biochemical recurrence-free survival
Side effects

Maximum androgen blockage was found to be more effective than bicalutamide 150 mg daily as immediate adjuvant therapy for high-risk localized prostate cancer after radical prostatectomy, resulting in longer biochemical recurrence-free survival.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

14.

Gynecomastia in Patients with Prostate Cancer: A Systematic Review.

Author: FagerlundAnders, CormioLuigi, PalangiLina, LewinRichard, Santanelli di PompeoFabio, ElanderAnna, SelvaggiGennaro

Gynecomastia treatment
Side effects

Bicalutamide-induced gynecomastia and/or mastodynia can effectively be managed by oral tamoxifen or radiotherapy without relevant side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

15.

Idiopathic stuttering priapism treated with salbutamol orally: a case report.

Author: MiglioriniF, PorcaroA B, BaldassarreR, ArtibaniW

Stuttering priapism treatment
Hypogonadal state
Infertility

Salbutamol, a beta-2-agonist, was effective in treating a case of stuttering priapism, a rare form of ischaemic priapism.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Subjective and Objective Effects of Androgen Ablation Therapy on Voice.

Author: SalturkZiya, ÇakırOzan, KumralTolgar Lütfi, YıldırımGüven, ÖtünçtemurAlper, AydoğduÏmran, UyarYavuz

Voice quality issues

ADT has adverse effects on the human voice. Prospective studies with long-term follow-up of a larger cohort are required for more detailed analysis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

19.

Prostate cancer risk after anti-androgen treatment for priapism.

Author: GoetzTabitha, BurnettArthur L

Improved priapism
Prostate cancer
Side effects

Anti-androgen therapy for recurrent ischemic priapism may mask prostate cancer, delaying diagnosis and treatment.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

20.

Current role of diethylstilbestrol in the management of advanced prostate cancer.

Author: BossetPierre-Olivier, AlbigesLaurence, SeisenThomas, de la Motte RougeThibault, PhéVéronique, BitkerMarc-Olivier, RouprêtMorgan

Prostate cancer treatment

Diethylstilbestrol (DES) is a hormone therapy that can be used to treat prostate cancer. This review summarizes recent clinical trials of DES in patients with castrate-resistant prostate cancer (CRPC), a form of prostate cancer that does not respond to standard hormone therapy. DES has been shown to be effective in treating CRPC, particularly when used as a second-line hormone therapy after other treatments have failed. Low doses of DES are associated with fewer side effects, including cardiovascular problems.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

21.

Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome.

Author: TessarisDaniele, MatarazzoPatrizia, MussaAlessandro, TuliGerdi, VernaFrancesca, FioreLudovica, LalaRoberto

Puberty treatment

This report describes a case of McCune-Albright Syndrome (MAS) treated with bicalutamide and anastrozole.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.

Author: FosterWilliam R, CarBruce D, ShiHong, LevesquePaul C, ObermeierMary T, GanJinping, ArezzoJoseph C, PowlinStephanie S, DinchukJoseph E, BalogAaron, SalvatiMark E, AttarRicardo M, GottardisMarco M

AR antagonist resistance
AR mutations

No new androgen receptor (AR) antagonists have been approved in over a decade despite the development of resistance to existing AR antagonists in prostate tumors. Mutations that increase AR activity and broaden ligand range contribute to treatment failure.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

23.

Androgen blockade for the treatment of high-flow priapism.

Author: MwamukondaKuwong B, ChiThomas, ShindelAlan W, LueTom F

Resolution of priapism
Erectile dysfunction

This study reviewed the management of high-flow priapism (HFP). The authors found that selective embolization is an effective treatment for HFP, but erectile dysfunction is a common complication.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Validation StudyResearch to assess the validity and reliability of new measurement methods or diagnostic tests.

Language : English

24.

Treatment of familial male-limited precocious puberty (testotoxicosis) with anastrozole and bicalutamide in a boy with a novel mutation in the luteinizing hormone receptor.

Author: MitreNaim, LteifAida

Precocious puberty treatment
Short-term side effects

This study reports the use of anastrozole and bicalutamide in a 5 year-old boy with familial male-limited precocious puberty. Clinical response showed decreased advancement of skeletal maturation, secondary sexual characteristics and aggressiveness with no short-term side effects.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

25.

[Adjuvant and neoadjuvant drug therapy for prostate cancer].

Author: MillerK, LeinM, SchostakM, SchraderM

Micrometastases eradication
Prostate cancer treatment
Overtreatment
Side effects

This abstract discusses the use of neoadjuvant and adjuvant hormone therapy for prostate cancer, providing recommendations based on available clinical studies. While there is no indication for neoadjuvant therapy before radical prostatectomy, adjuvant therapy may be considered for patients with lymph node-positive tumors or locally advanced tumors.

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : German

26.

Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.

Author: PetitJoshua H, GluckClifford, KigerW S, HenryD Laury, KarasiewiczCarol, TalcottJames, BergSolomon, HolupkaEdward, KaplanIrving

Fewer sexual side effects
Reduced prostate volume
Urinary morbidity

Bicalutamide is associated with fewer patient-reported sexual side effects and similar urinary morbidity compared with luteinizing hormone-releasing hormone analogues.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.